Acute myeloid leukemia: advancing clinical trials and promising therapeutics

Naval Daver, Jorge Cortes, Hagop Kantarjian, Farhad Ravandi

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutations, leukemia specific antigens and signal transduction pathways has ushered in a new era of therapy. In many circumstances the response rates with such targeted or antibody-based therapies are superior to those achieved with standard therapy and with decreased toxicity. In this review we discuss novel therapies in AML with a focus on two major areas of unmet need: (1) single agent and combination strategies to improve frontline therapy in elderly patients with AML and (2) molecularly targeted therapies in the frontline and salvage setting in all patients with AML.

Original languageEnglish (US)
Pages (from-to)433-445
Number of pages13
JournalExpert Review of Hematology
Volume9
Issue number5
DOIs
StatePublished - May 3 2016
Externally publishedYes

Keywords

  • AML
  • clinical trials
  • molecular therapy
  • monoclonal antibodies
  • multikinase inhibitors

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Acute myeloid leukemia: advancing clinical trials and promising therapeutics'. Together they form a unique fingerprint.

  • Cite this